Screening Innovations and 3D Cell Culture Assay Developments
Showcased at ELRIG
New Tech Aids Drug Discovery
In Scientific Publishing, Sharing Is Caring
The Saga for Open-Access Research Continues
Cell-Free DNA Drives Liquid Biopsy Testing
Researchers Are Diligently Finding Ways to Use Scraps of cfDNA in Clinically Relevant Ways
Raising the Bar of Cell Line Authentication
Researchers May Be Slow to Implement Protocols Unless They Are Pressured
For full access to this article login to GEN Select now.
Hopes Dashed for Alzheimer's Patients
The Latest Phase III Failure Perpetuates Skepticism about Developing Drugs for AD
- Hopes for a new drug to treat the symptoms of Alzheimer disease (AD) diminished again on March 3 when Pfizer and Medivation reported Phase III results showing that Dimebon failed to meet its co-primary and secondary efficacy endpoints. Pfizer had shelled out $225 million up front and agreed to ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.